BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Inclusion Criteria: 1. age between 8 and 65 years; 2. diagnosis of histologically confirmed advanced bone and soft tissue sarcoma excluding adipocytic tumor; 3. identification of pulmonary lesion is mandatory; 4. refractory to prior treatment consisted of standard National Comprehensive Cancer Network (NCCN) guideline recommended first-line chemotherapy; 5. Eastern Cooperative Oncology Group(ECOG) performance status 0-2 with a life expectancy \>3 months; 6. adequate renal, hepatic, and hemopoietic function;normal or controlled blood pressure; 7. advanced stage that complete surgical resection of all lesions are infeasible; 8. no serious thoracic comorbidities with adequate pulmonary function for daily living; 9. previously treated with tyrosine kinase inhibitors (TKIs) for less than 8 weeks but off treatment due to manageable complications such as wound complications or pneumothorax without adequate interventions. The complications is resolved and disappeared at enrollment. Exclusion Criteria: 1. have had other kinds of malignant tumors at the same time; 2. cardiac insufficiency or arrhythmia; 3. uncontrolled complications, such as diabetes mellitus and so on; 4. coagulation disorders or Hemorrhagic diseases ; 5. pleural or peritoneal effusion that needs to be handled by surgical treatment; 6. combined with other infections or wound complications; 7. wound dystrophy, poor soft-tissue around implantation risky of non-healing given angiogenesis inhibitor at baseline; 8. previously treated with VEGFR TKIs for more than 8 weeks 9. previous treated with VEGFR TKIs but off treatment due to oncological assessment or dose-limiting complications given adequate interventions.